INX-315 Granted FDA Fast Track Designation for Platinum-Resistant or Refractory Ovarian Cancer
Pharmacy Times,
The FDA granted a fast track designation to INX-315 (Incyclix Bio, LLC) for the treatment of cyclin E1 (CCNE1)-amplified…
Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition
OncLive,
Joyce F. Liu, MD, MPHJoyce F. Liu, MD, MPH Although recent advances have added more targeted agents to the ovarian cancer…
Repare Therapeutics: What Roche And Bristol-Myers Squibb See
Seeking Alpha,
Follow Summary Today, we take our first look at a promising developmental concern called Repare Therapeutics.